[go: up one dir, main page]

MXPA04001500A - Compuestos que tienen un efecto sobre la glucocinasa. - Google Patents

Compuestos que tienen un efecto sobre la glucocinasa.

Info

Publication number
MXPA04001500A
MXPA04001500A MXPA04001500A MXPA04001500A MXPA04001500A MX PA04001500 A MXPA04001500 A MX PA04001500A MX PA04001500 A MXPA04001500 A MX PA04001500A MX PA04001500 A MXPA04001500 A MX PA04001500A MX PA04001500 A MXPA04001500 A MX PA04001500A
Authority
MX
Mexico
Prior art keywords
formula
compounds
glucokinase
compounds effecting
relates
Prior art date
Application number
MXPA04001500A
Other languages
English (en)
Inventor
Howard Block Michael
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of MXPA04001500A publication Critical patent/MXPA04001500A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/84—Nitriles
    • C07D213/85—Nitriles in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38—Nitrogen atoms
    • C07D231/40—Acylated on said nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/44—Nitrogen atoms not forming part of a nitro radical
    • C07D233/48—Nitrogen atoms not forming part of a nitro radical with acyclic hydrocarbon or substituted acyclic hydrocarbon radicals, attached to said nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/20—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/20—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D241/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with nitrogen atoms directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D261/14—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/44—Acylated amino or imino radicals
    • C07D277/46—Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D277/82—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
    • C07D285/125—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • C07D285/135—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/66—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Furan Compounds (AREA)

Abstract

La invencion se refiere al uso de un compuesto de formula (I) o una sal, solvato o profarmaco del mismo, en donde R1, R2, R3, n y m son como se describen en la especificacion, en la preparacion de un medicamento para el tratamiento o prevencion de una condicion de enfermedad mediada a traves de glucocinasa (GLK), tal como diabetes tipo 2. La invencion tambien se relaciona con un grupo novedoso de compuestos de formula (I) y con metodos para preparar compuestos de formula (I).
MXPA04001500A 2001-08-17 2002-08-15 Compuestos que tienen un efecto sobre la glucocinasa. MXPA04001500A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0102764A SE0102764D0 (sv) 2001-08-17 2001-08-17 Compounds
PCT/GB2002/003745 WO2003015774A1 (en) 2001-08-17 2002-08-15 Compounds effecting glucokinase

Publications (1)

Publication Number Publication Date
MXPA04001500A true MXPA04001500A (es) 2004-05-14

Family

ID=20285065

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA04001500A MXPA04001500A (es) 2001-08-17 2002-08-15 Compuestos que tienen un efecto sobre la glucocinasa.

Country Status (32)

Country Link
US (3) US7390908B2 (es)
EP (12) EP1661568B1 (es)
JP (2) JP3987829B2 (es)
KR (1) KR100920439B1 (es)
CN (4) CN101584691A (es)
AR (1) AR037898A1 (es)
AT (11) ATE359781T1 (es)
AU (1) AU2002321462B2 (es)
BR (1) BR0212008A (es)
CA (1) CA2457410C (es)
CO (1) CO5560563A2 (es)
CY (5) CY1105746T1 (es)
DE (11) DE60227121D1 (es)
DK (5) DK1661569T3 (es)
ES (10) ES2312051T3 (es)
HK (10) HK1089958A1 (es)
HU (1) HUP0401213A3 (es)
IL (2) IL160219A0 (es)
IS (1) IS7150A (es)
MX (1) MXPA04001500A (es)
MY (1) MY146279A (es)
NO (1) NO20040686L (es)
NZ (1) NZ531193A (es)
PL (1) PL368970A1 (es)
PT (5) PT1568367E (es)
RU (1) RU2329043C9 (es)
SE (1) SE0102764D0 (es)
SI (5) SI1669068T1 (es)
TW (1) TWI333855B (es)
UA (1) UA83182C2 (es)
WO (1) WO2003015774A1 (es)
ZA (1) ZA200401015B (es)

Families Citing this family (144)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0102299D0 (sv) 2001-06-26 2001-06-26 Astrazeneca Ab Compounds
SE0102300D0 (sv) * 2001-06-26 2001-06-26 Astrazeneca Ab Compounds
SE0102764D0 (sv) * 2001-08-17 2001-08-17 Astrazeneca Ab Compounds
JP2004123732A (ja) * 2002-09-10 2004-04-22 Takeda Chem Ind Ltd ５員複素環化合物
EP1541564A1 (en) * 2002-09-10 2005-06-15 Takeda Pharmaceutical Company Limited Five-membered heterocyclic compounds
EP1549626A1 (en) 2002-10-03 2005-07-06 Novartis AG Substituted (thiazol-2-yl) -amide or sulfonamide as glycokinase activators useful in the treatment of type 2 diabetes
GB0226930D0 (en) 2002-11-19 2002-12-24 Astrazeneca Ab Chemical compounds
GB0226931D0 (en) 2002-11-19 2002-12-24 Astrazeneca Ab Chemical compounds
PL378117A1 (pl) 2003-02-11 2006-03-06 Prosidion Limited Tricyklopodstawione związki amidowe
BRPI0407283A (pt) 2003-02-13 2006-01-31 Banyu Pharma Co Ltd Composto, composição farmacêutica, e, agente ativador de glucoquinase, agentes terapêuticos e/ou agentes preventivos para diabetes melito e obesidade
NZ541824A (en) 2003-02-26 2010-04-30 Banyu Pharma Co Ltd Heteroarylcarbamoylbenzene derivatives as glucokinase activators
US20050032868A1 (en) * 2003-05-02 2005-02-10 Garofalo Albert W. Selected substituted pyrazole derivatives and related compounds as bradykinin B1 receptor antagonists
ES2314418T3 (es) 2003-05-02 2009-03-16 Elan Pharmaceuticals, Inc. Derivados de amidas del acido 4-bromo-5-(2-clorobenzoilamino)-1h-pirazol-3-carboxicilico y compuestos relacionados como antagonistas del receptor b1 de bradiquinina para el tratamiento de enfermedades inflamatorias.
EP1638556B1 (en) * 2003-06-20 2008-04-02 F. Hoffmann-La Roche Ag 2-aminobenzothiazoles as cb1 receptor inverse agonists
ES2222822B1 (es) 2003-07-28 2005-12-16 Laboratorios Farmaceuticos Rovi, S.A. Diamidas de aminoacidos en posicion no alfa utiles como adyuvantes para la administracion de agentes biologicos activos.
EP1680109A4 (en) 2003-10-07 2009-05-06 Renovis Inc AMIDE DERIVATIVES AS ION CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE DERIVATIVES
GB0325402D0 (en) * 2003-10-31 2003-12-03 Astrazeneca Ab Compounds
GB0328178D0 (en) * 2003-12-05 2004-01-07 Astrazeneca Ab Compounds
KR20070007103A (ko) * 2004-02-18 2007-01-12 아스트라제네카 아베 벤즈아미드 유도체 및 이의 글루코키나아제 활성화제로서의용도
EP1718625A1 (en) * 2004-02-18 2006-11-08 AstraZeneca AB Compounds
RU2006138426A (ru) 2004-04-02 2008-05-10 Новартис АГ (CH) Производные тиазолопиридина, содержащие их фармацевтические композиции и способы лечения состояний, опосредованных глюкокиназой
EP2305352A1 (en) 2004-04-02 2011-04-06 Merck Sharp & Dohme Corp. 5-alpha-reductase inhibitors for use in the treatment of men with metabolic and anthropometric disorders
AU2005229416B2 (en) 2004-04-02 2009-03-26 Novartis Ag Sulfonamide-thiazolpyridine derivatives as glucokinase activators useful the treatment of type 2 diabetes
TW200600086A (en) * 2004-06-05 2006-01-01 Astrazeneca Ab Chemical compound
KR100739367B1 (ko) * 2004-07-14 2007-07-16 크리스탈지노믹스(주) 설파마이드 유도체 및 이를 함유하는 지방대사 촉진용약학적 조성물
GB0423044D0 (en) * 2004-10-16 2004-11-17 Astrazeneca Ab Compounds
GB0423043D0 (en) * 2004-10-16 2004-11-17 Astrazeneca Ab Compounds
WO2006040527A1 (en) 2004-10-16 2006-04-20 Astrazeneca Ab Process for making phenoxy benzamide compounds
US7576099B2 (en) 2005-02-28 2009-08-18 Renovis, Inc. Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same
CA2609394A1 (en) * 2005-05-23 2006-11-30 Masaki Takagi Pyrazole compound and therapeutic agent for diabetes comprising the same
EP1891069A1 (en) * 2005-05-24 2008-02-27 AstraZeneca AB 2-phenyl substituted imidazol [4,5b]pyridine/ pyrazine and purine derivatives as glucokinase modulators
TW200714597A (en) * 2005-05-27 2007-04-16 Astrazeneca Ab Chemical compounds
GB0510852D0 (en) * 2005-05-27 2005-07-06 Astrazeneca Ab Chemical compounds
US7642259B2 (en) 2005-07-09 2010-01-05 Astrazeneca Ab Heteroaryl benzamide derivatives for use as GLK activators in the treatment of diabetes
US20080234273A1 (en) * 2005-07-09 2008-09-25 Mckerrecher Darren Heteroaryl Benzamide Derivatives for Use as Glk Activators in the Treatment of Diabetes
GB0514173D0 (en) * 2005-07-09 2005-08-17 Astrazeneca Ab Chemical compounds
JP2009500442A (ja) * 2005-07-09 2009-01-08 アストラゼネカ アクチボラグ ２型糖尿病を処置するためのグルコキナーゼのモジュレーターとしての２−ヘテロシクリルオキシベンゾイルアミノヘテロシクリル化合物
ES2426345T3 (es) 2005-07-20 2013-10-22 Eli Lilly And Company Compuesto unidos en posición 1-amino
US9202182B2 (en) * 2005-08-11 2015-12-01 International Business Machines Corporation Method and system for analyzing business architecture
JP2007063225A (ja) 2005-09-01 2007-03-15 Takeda Chem Ind Ltd イミダゾピリジン化合物
WO2007039177A2 (en) 2005-09-29 2007-04-12 Sanofi-Aventis Phenyl- and pyridinyl- 1, 2 , 4 - oxadiazolone derivatives, processes for their preparation and their use as pharmaceuticals
GT200600428A (es) 2005-09-30 2007-05-21 Compuestos organicos
GT200600429A (es) 2005-09-30 2007-04-30 Compuestos organicos
US7863329B2 (en) 2005-11-17 2011-01-04 Eli Lilly And Company Glucagon receptor antagonists, preparation and therapeutic uses
TW200738621A (en) 2005-11-28 2007-10-16 Astrazeneca Ab Chemical process
EP2001875A2 (en) 2006-03-08 2008-12-17 Takeda San Diego, Inc. Glucokinase activators
WO2007122482A1 (en) * 2006-04-20 2007-11-01 Pfizer Products Inc. Fused phenyl amido heterocyclic compounds for the prevention and treatment of glucokinase-mediated diseases
EP2019823B1 (en) * 2006-04-28 2010-11-24 TransTech Pharma, Inc. Benzamide glucokinase activators
US7880012B2 (en) 2006-04-28 2011-02-01 Transtech Pharma, Inc. Benzamide glucokinase activators
US8211925B2 (en) 2006-04-28 2012-07-03 Transtech Pharma, Inc. Benzamide glucokinase activators
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
UA93548C2 (uk) 2006-05-05 2011-02-25 Айерем Елелсі Сполуки та композиції як модулятори хеджхогівського сигнального шляху
ATE522518T1 (de) 2006-05-31 2011-09-15 Takeda San Diego Inc Indazol- und isoindolderivate als glucokinaseaktivierende stoffe
US7910747B2 (en) 2006-07-06 2011-03-22 Bristol-Myers Squibb Company Phosphonate and phosphinate pyrazolylamide glucokinase activators
US7888504B2 (en) * 2006-07-06 2011-02-15 Bristol-Myers Squibb Company Glucokinase activators and methods of using same
AU2007278261A1 (en) 2006-07-24 2008-01-31 F. Hoffmann-La Roche Ag Pyrazoles as glucokinase activators
KR101202240B1 (ko) 2006-08-24 2012-11-16 유니버시티 오브 테네시 리서치 파운데이션 치환된 아실아닐리드 및 그의 사용 방법
EP2069287A1 (en) 2006-09-11 2009-06-17 Syngeta Participations AG Insecticidal compounds
AR063028A1 (es) 2006-10-06 2008-12-23 Banyu Pharma Co Ltd Derivados heterociclicos de piridin-2-carboxamida activadores de glucoquinasas, utiles para el tratamiento de diabetes y obesidad y composiciones farmaceuticas que los contienen.
US20110039893A1 (en) * 2006-10-11 2011-02-17 Takeda Pharmaceutical Company Limited Gsk-3beta inhibitor
TW200825063A (en) * 2006-10-23 2008-06-16 Astrazeneca Ab Chemical compounds
CN101563330B (zh) * 2006-10-26 2012-06-27 阿斯利康(瑞典)有限公司 作为葡糖激酶(glk)激活剂的苯甲酰氨基杂环化合物
SA07280576B1 (ar) * 2006-10-26 2011-06-22 استرازينيكا ايه بي مركبات بنزويل أمينو سيكليل غير متجانسة بأعتبارها عوامل منشطة للجلوكوكيناز
TW200827346A (en) 2006-11-03 2008-07-01 Astrazeneca Ab Chemical compounds
WO2008062739A1 (fr) * 2006-11-20 2008-05-29 Japan Tobacco Inc. Pyrazoles et leur utilisation en tant que médicaments
BRPI0720254A2 (pt) * 2006-12-15 2014-01-07 Glaxo Group Ltd Derivados de benzamida como agonistas do receptor ep4
US8163779B2 (en) 2006-12-20 2012-04-24 Takeda San Diego, Inc. Glucokinase activators
BRPI0721143A2 (pt) * 2006-12-21 2014-03-11 Astrazeneca Ab Forma cristalina do composto processo para a formação da mesma, uso de um composto, método para tratar doenças mediadas por ativador de glicocinase
WO2008083124A1 (en) 2006-12-28 2008-07-10 Rigel Pharmaceuticals, Inc. N-substituted-heterocycloalkyloxybenzamide compounds and methods of use
TW200836719A (en) 2007-02-12 2008-09-16 Astrazeneca Ab Chemical compounds
EP2125735B1 (en) 2007-02-28 2012-06-27 Advinus Therapeutics Private Limited 2,2,2-tri-substituted acetamide derivatives as glucokinase activators, their process and pharmaceutical application
US8173645B2 (en) 2007-03-21 2012-05-08 Takeda San Diego, Inc. Glucokinase activators
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
CA2688136A1 (en) 2007-06-08 2008-12-11 Advinus Therapeutics Private Limited Pyrrole-2-carboxamide derivatives as glucokinase activators, their process and pharmaceutical application
EP2170852A1 (en) 2007-06-11 2010-04-07 Bristol-Myers Squibb Company 1, 3 - dihydroxy substituted phenylamide glucokinase activators
CA2695517C (en) * 2007-08-03 2016-09-20 J. Edward Semple Alkylsulfonyl-substituted thiazolide compounds
US8314091B2 (en) 2007-08-20 2012-11-20 Msd Oss B.V. N-benzyl,N'-arylcarbonylpiperazine derivatives
TW200922582A (en) * 2007-08-20 2009-06-01 Organon Nv N-benzyl, N'-arylcarbonylpiperazine derivatives
US9340506B2 (en) 2007-10-08 2016-05-17 Advinus Therapeutics Limited Acetamide derivatives as glucokinase activators, their process and medicinal applications
AU2008310519B2 (en) * 2007-10-08 2013-05-02 Advinus Therapeutics Private Limited Acetamide derivatives as glucokinase activators, their process and medicinal applications
WO2009046802A1 (en) * 2007-10-09 2009-04-16 Merck Patent Gmbh N- ( pyrazole- 3 -yl) -benzamide derivatives as glucokinase activators
BRPI0818658A2 (pt) * 2007-10-09 2015-04-14 Merck Patent Ges Mit Beschränkter Haftung Derivados de piridina úteis como ativadores de glicoquinase
US7741327B2 (en) 2008-04-16 2010-06-22 Hoffmann-La Roche Inc. Pyrrolidinone glucokinase activators
US8258134B2 (en) 2008-04-16 2012-09-04 Hoffmann-La Roche Inc. Pyridazinone glucokinase activators
CA2722139C (en) 2008-04-23 2017-04-11 Rigel Pharmaceuticals, Inc. Carboxamide compounds for the treatment of metabolic disorders
KR101006311B1 (ko) * 2008-06-27 2011-01-06 김정이 온수를 이용한 황토 온열매트 및 그 제조방법
WO2010009319A2 (en) 2008-07-16 2010-01-21 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
KR20110052676A (ko) 2008-08-04 2011-05-18 아스트라제네카 아베 피라졸로[3,4]피리미딘-4-일 유도체 및 당뇨병 및 비만을 치료하기 위한 이의 용도
EP2348857B1 (en) 2008-10-22 2016-02-24 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
US8329914B2 (en) 2008-10-31 2012-12-11 Merck Sharp & Dohme Corp Cyclic benzimidazole derivatives useful as anti-diabetic agents
US8759539B2 (en) 2008-11-17 2014-06-24 Merck Sharp & Dohme Corp. Substituted bicyclic amines for the treatment of diabetes
WO2010085769A1 (en) 2009-01-26 2010-07-29 Nanoink, Inc. Large area, homogeneous array fabrication including homogeneous substrates
US8214916B2 (en) 2009-01-26 2012-07-03 Nanoink, Inc. Large area, homogeneous array fabrication including leveling with use of bright spots
AU2010206595A1 (en) 2009-01-26 2011-07-28 Nanoink, Inc. Large area, homogeneous array fabrication including substrate temperature control
GB0902434D0 (en) * 2009-02-13 2009-04-01 Astrazeneca Ab Chemical process
GB0902406D0 (en) * 2009-02-13 2009-04-01 Astrazeneca Ab Crystalline polymorphic form
AR076221A1 (es) * 2009-04-09 2011-05-26 Astrazeneca Ab Derivado de pirazol [4,5-e] pirimidina y su uso para tratar diabetes y obesidad
AR076220A1 (es) 2009-04-09 2011-05-26 Astrazeneca Ab Derivados de pirazol [4,5 - e] pirimidina
NZ596538A (en) 2009-05-12 2014-04-30 Romark Lab Lc Haloalkyl heteroaryl benzamide compounds
BR122020003634B8 (pt) 2009-06-26 2021-07-27 Romark Laboratories Lc uso de nitazoxanida, tizoxanida ou sal farmaceuticalmente aceitável do mesmo no tratamento de uma doença semelhante a influenza
WO2011011506A1 (en) 2009-07-23 2011-01-27 Schering Corporation Spirocyclic oxazepine compounds as stearoyl-coenzyme a delta-9 desaturase inhibitors
US20120220567A1 (en) 2009-07-23 2012-08-30 Shipps Jr Gerald W Benzo-fused oxazepine compounds as stearoyl-coenzyme a delta-9 desaturase inhibitors
CA2768232A1 (en) * 2009-07-31 2011-02-03 Cadila Healthcare Limited Substituted benzamide derivatives as glucokinase (gk) activators
WO2011081280A2 (en) * 2009-09-22 2011-07-07 Yuhan Corporation Novel glucokinase activators and processes for the preparation thereof
PL2480539T3 (pl) * 2009-09-25 2013-11-29 Bayer Cropscience Ag N-(1,2,5-oksadiazol-3-ilo)benzamidy i ich zastosowanie jako herbicydy
US8222416B2 (en) 2009-12-14 2012-07-17 Hoffmann-La Roche Inc. Azaindole glucokinase activators
WO2011106273A1 (en) 2010-02-25 2011-09-01 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
EP2547667A1 (en) * 2010-03-18 2013-01-23 Takeda California, Inc. Process for the production of 2-amino-5-fluorothiazole
WO2011135355A1 (en) 2010-04-29 2011-11-03 Astrazeneca Ab 3-{ [5 -(azetidin-1-ylcarbonyl)pyrazin-2 -yl] oxy} -5-{ [(1s) -2 -hydroxy- 1 -methylethyl]oxy} -n- (5 -methylpyrazin-2-) benzamid monohydrate
US8178689B2 (en) 2010-06-17 2012-05-15 Hoffman-La Roche Inc. Tricyclic compounds
US8697911B2 (en) 2010-07-07 2014-04-15 Boehringer Ingelheim International Gmbh Rho kinase inhibitors
US9079880B2 (en) 2010-07-07 2015-07-14 Boehringer Ingelheim International Gmbh Rho kinase inhibitors
WO2012027331A1 (en) 2010-08-27 2012-03-01 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
EP2630144B1 (en) 2010-10-19 2016-09-07 Boehringer Ingelheim International GmbH Rho kinase inhibitors
MX2013004724A (es) * 2010-11-01 2013-08-29 Romark Lab Lc Compuestos de tiazolida alquilsulfinilo-sustituidos.
CN103476258B (zh) 2011-02-25 2017-04-26 默沙东公司 用作抗糖尿病药剂的新的环状氮杂苯并咪唑衍生物
CA2870488A1 (en) 2012-04-16 2013-10-24 Kaneq Pharma Inc. Fused aromatic phosphonate derivatives as precursors to ptp-1b inhibitors
DK2872482T3 (da) 2012-07-13 2020-09-21 Oncternal Therapeutics Inc En fremgangsmåde til behandling af brystkræft med selektiv androgenreceptormodulator (sarm)
US10258596B2 (en) 2012-07-13 2019-04-16 Gtx, Inc. Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
US10314807B2 (en) 2012-07-13 2019-06-11 Gtx, Inc. Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
US9744149B2 (en) 2012-07-13 2017-08-29 Gtx, Inc. Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)
US9622992B2 (en) 2012-07-13 2017-04-18 Gtx, Inc. Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)
US10987334B2 (en) 2012-07-13 2021-04-27 University Of Tennessee Research Foundation Method of treating ER mutant expressing breast cancers with selective androgen receptor modulators (SARMs)
US9969683B2 (en) 2012-07-13 2018-05-15 Gtx, Inc. Method of treating estrogen receptor (ER)-positive breast cancers with selective androgen receptor modulator (SARMS)
BR112015002080A2 (pt) 2012-08-02 2017-07-04 Merck Sharp & Dohme composto, composição farmacêutica, uso de um composto, e, método de tratamento ou de prevenção de um transtorno, de uma condição ou de uma doença
CN102942541B (zh) * 2012-12-04 2014-07-23 西北师范大学 一种受体化合物及其合成和在比色检测氟离子中的应用
US9840512B2 (en) 2013-02-22 2017-12-12 Merck Sharp & Dohme Corp. Antidiabetic bicyclic compounds
US9650375B2 (en) 2013-03-14 2017-05-16 Merck Sharp & Dohme Corp. Indole derivatives useful as anti-diabetic agents
AU2014254392B2 (en) * 2013-03-15 2018-05-24 Epizyme, Inc. Substituted benzene compounds
US9243001B2 (en) 2013-03-15 2016-01-26 Epizyme, Inc. Substituted benzene compounds
ES2981866T3 (es) 2013-06-05 2024-10-10 Bausch Health Ireland Ltd Agonistas ultrapuros de guanilato ciclasa C, método de elaboración y uso de los mismos
WO2015051496A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
CN104672219A (zh) * 2015-02-13 2015-06-03 佛山市赛维斯医药科技有限公司 一类含葡萄糖酰胺结构的葡萄糖激酶活化剂及其用途
CN104672218A (zh) * 2015-02-13 2015-06-03 佛山市赛维斯医药科技有限公司 含葡萄糖酰胺结构的葡萄糖激酶活化剂、制备方法及其在治疗2型糖尿病上的用途
WO2018106518A1 (en) 2016-12-06 2018-06-14 Merck Sharp & Dohme Corp. Antidiabetic heterocyclic compounds
EP3558298A4 (en) 2016-12-20 2020-08-05 Merck Sharp & Dohme Corp. ANTIDIABETIC SPIROCHROMAN COMPOUNDS
EP3601250A4 (en) * 2017-03-27 2020-11-25 Pharmakea, Inc. APOPTOSIS SIGNAL REGULATION KINASE 1 (ASK 1) INHIBITOR COMPOUNDS
GB201714777D0 (en) 2017-09-14 2017-11-01 Univ London Queen Mary Agent
CN110606831A (zh) * 2018-06-14 2019-12-24 上海度德医药科技有限公司 一种Iclaprim的新中间体及其制备方法和应用
CN109879818A (zh) * 2019-04-04 2019-06-14 安徽丰乐农化有限责任公司 N-(4,6-二甲氧基嘧啶-2-基)-4-甲砜基-2-硝基苯甲酰胺的合成方法
JP2022537833A (ja) * 2019-06-24 2022-08-30 ベネボレントエーアイ バイオ リミティド 新規化合物と方法
KR102138149B1 (ko) * 2019-08-29 2020-07-27 솔브레인 주식회사 박막 형성용 성장 억제제, 이를 이용한 박막 형성 방법 및 이로부터 제조된 반도체 기판
CN114591192B (zh) * 2020-12-04 2024-06-21 江西仰立新材料有限公司 一种n-环丙甲基苯胺类化合物的制备方法

Family Cites Families (203)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2750393A (en) * 1954-12-01 1956-06-12 Sterling Drug Inc Iodinated 5-henzamidotetrazoles and preparation thereof
US2967194A (en) * 1958-05-15 1961-01-03 Pennsalt Chemicals Corp 4-trifluoromethylsalicylamides
FR1526074A (fr) 1967-03-22 1968-05-24 Rech S Ind S O R I Soc D Méthoxy-phényl-amino-2-thiazoles, leurs amides et leurs procédés de préparation
GB1352415A (en) 1970-05-03 1974-05-08 Boots Co Ltd Esters of substituted nicotine acids
FR2088019A1 (en) 1970-05-08 1972-01-07 Rabot Ets David Esters of 2 and 6-substituted nicotinic acids - with vasomotor active
CS173097B1 (es) 1972-12-01 1977-02-28
GB1400540A (en) * 1972-12-06 1975-07-16 Smith Kline French Lab Salicylamides and compositions thereof
US4009174A (en) * 1972-12-08 1977-02-22 The Boots Company Limited Esters of substituted nicotinic acids
GB1437800A (en) 1973-08-08 1976-06-03 Phavic Sprl Derivatives of 2-benzamido-5-nitro-thiazoles
JPS5734314B2 (es) 1973-12-22 1982-07-22
GB1561350A (en) 1976-11-05 1980-02-20 May & Baker Ltd Benzamide derivatives
FR2344284A1 (fr) * 1976-03-17 1977-10-14 Cerm Cent Europ Rech Mauvernay Nouveaux composes tricycliques a cycle furannique et leur application comme antidepresseurs
GB1588242A (en) 1977-10-28 1981-04-23 May & Baker Ltd N-(tetrazol-5-yl)-salicylamide derivatives
US4474792A (en) * 1979-06-18 1984-10-02 Riker Laboratories, Inc. N-Tetrazolyl benzamides and anti-allergic use thereof
JPS5721320A (en) 1980-07-11 1982-02-04 Chugai Pharmaceut Co Ltd Blood sugar level depressing agent
JPS5775962A (en) 1980-10-29 1982-05-12 Shionogi & Co Ltd 2-alkoxybenzamide derivative
FR2493848B2 (fr) 1980-11-07 1986-05-16 Delalande Sa Nouveaux derives des nor-tropane et granatane, leur procede de preparation et leur application en therapeutique
JPS5869812A (ja) 1981-10-22 1983-04-26 Chugai Pharmaceut Co Ltd 血糖降下剤
JPS59139357A (ja) * 1983-01-28 1984-08-10 Torii Yakuhin Kk アミジン誘導体
JPS61205937A (ja) 1985-03-09 1986-09-12 Konishiroku Photo Ind Co Ltd ハロゲン化銀カラ−写真感光材料
JPS62142168A (ja) 1985-10-16 1987-06-25 Mitsubishi Chem Ind Ltd チアゾ−ル誘導体及びそれを有効成分とするロイコトリエンきつ抗剤
JPS62158252A (ja) * 1985-12-28 1987-07-14 Kirin Brewery Co Ltd ４−アミノピリジンベンズアミド誘導体
CA1327358C (en) 1987-11-17 1994-03-01 Morio Fujiu Fluoro cytidine derivatives
JP2852659B2 (ja) 1988-03-03 1999-02-03 富山化学工業株式会社 ピペラジン誘導体およびその塩
DE3822449A1 (de) 1988-07-02 1990-01-04 Henkel Kgaa Oxidationshaarfaerbemittel mit neuen kupplern
JPH03181465A (ja) 1989-12-11 1991-08-07 Takeda Chem Ind Ltd キノリン誘導体
JPH04300832A (ja) 1991-03-29 1992-10-23 Tsumura & Co ２，４−ジアミノ−１，３，５−トリアジン誘導体を有　　　　　　　　　　　効成分とするロイコトリエン拮抗剤
JPH04300874A (ja) 1991-03-29 1992-10-23 Tsumura & Co 新規２，４−ジアミノ−１，３，５−トリアジン誘導体
US5258407A (en) 1991-12-31 1993-11-02 Sterling Winthrop Inc. 3,4-disubstituted phenols-immunomodulating agents
US5466715A (en) 1991-12-31 1995-11-14 Sterling Winthrop Inc. 3,4-disubstituted phenols-immunomodulating agents
US5273986A (en) * 1992-07-02 1993-12-28 Hoffmann-La Roche Inc. Cycloalkylthiazoles
JPH0627025A (ja) 1992-07-06 1994-02-04 Toto Ltd 分子認識機能膜及びこれを用いたセンサー
WO1994004525A1 (en) 1992-08-20 1994-03-03 Otsuka Pharmaceutical Company, Limited Benzoheterocyclic compounds as oxytocin and vasopressin antagonists
PT672031E (pt) 1992-12-02 2003-06-30 Pfizer Dieteres de catecol como inibidores selectivos de pde iv
EP0619116A3 (en) 1993-04-05 1994-11-23 Hoechst Japan Use of synthetic retinoids for osteopathy.
GB9307527D0 (en) 1993-04-13 1993-06-02 Fujisawa Pharmaceutical Co New venzamide derivatives,processes for the preparation thereof and pharmaceutical composition comprising the same
ES2123156T3 (es) 1993-08-24 1999-01-01 Medivir Ab Compuestos y procedimientos de inhibicion de hiv y virus semejantes.
GB9401460D0 (en) 1994-01-26 1994-03-23 Rhone Poulenc Rorer Ltd Compositions of matter
WO1995035298A1 (fr) 1994-06-21 1995-12-28 Otsuka Pharmaceutical Factory, Inc. DERIVE DE PYRAZOLO[1,5-a]PYRIMIDINE
US5661153A (en) 1994-07-19 1997-08-26 Japan Energy Corporation 1-arylpyrimidine derivatives and pharmaceutical use thereof
US5792109A (en) 1994-09-01 1998-08-11 Leland L. Ladd Irrigation pump and system
GB9420557D0 (en) 1994-10-12 1994-11-30 Zeneca Ltd Aromatic compounds
JPH08143565A (ja) 1994-11-16 1996-06-04 Fujisawa Pharmaceut Co Ltd ベンズアミド化合物
US5510478A (en) * 1994-11-30 1996-04-23 American Home Products Corporation 2-arylamidothiazole derivatives with CNS activity
US5672750A (en) * 1994-12-16 1997-09-30 Eastman Chemical Company Preparation of aromatic amides from carbon monoxide, an amine and an aromatic chloride
US5962682A (en) 1994-12-20 1999-10-05 Hoffmann-La Roche Inc. Aryl- and hetaryl-sulfonamide derivatives, their preparation and their use as endothelin antagonists
US5700796A (en) 1995-01-17 1997-12-23 American Cyanamid Company Tricyclic benzazepine vasopressin antagonists
US5696112A (en) 1995-01-17 1997-12-09 American Cyanamid Company Fused heterocyclic azepines as vasopressin antagonists
AR002459A1 (es) 1995-01-17 1998-03-25 American Cyanamid Co Antagonistas de vasopresina de benzacepina triciclicos, una composicion farmaceutica que los contiene, un metodo para tratar enfermedades y unprocedimiento para su preparacion.
US5532235A (en) 1995-01-17 1996-07-02 American Cyanamid Company Tricyclic benzazepine vasopressin antagonists
US5536718A (en) 1995-01-17 1996-07-16 American Cyanamid Company Tricyclic benzazepine vasopressin antagonists
US5849735A (en) * 1995-01-17 1998-12-15 American Cyanamid Company Tricyclic benzazepine vasopressin antagonists
US5753648A (en) 1995-01-17 1998-05-19 American Cyanamid Company Tricyclic benzazepine vasopressin antagonists
JPH08301760A (ja) 1995-05-10 1996-11-19 Shiseido Co Ltd 皮膚外用剤
WO1996036619A1 (fr) 1995-05-18 1996-11-21 Zeria Pharmaceutical Co., Ltd. Derives d'aminothiazole, medicament contenant ces derives et produit intermediaire obtenu durant la production des composes
JP3168915B2 (ja) 1995-05-25 2001-05-21 田辺製薬株式会社 医薬組成物
GB9511694D0 (en) 1995-06-09 1995-08-02 Fujisawa Pharmaceutical Co Benzamide derivatives
US5712270A (en) * 1995-11-06 1998-01-27 American Home Products Corporation 2-arylamidothiazole derivatives with CNS activity
JP3735741B2 (ja) 1995-11-24 2006-01-18 株式会社大塚製薬工場 縮環ピリミジン誘導体
GB9526558D0 (en) 1995-12-27 1996-02-28 Fujisawa Pharmaceutical Co Heterobicyclic derivatives
AU2595697A (en) 1996-03-29 1997-10-22 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
DE69717453T2 (de) 1996-06-06 2003-07-10 Otsuka Pharmaceutical Factory, Inc. Amid derivate
JPH10101672A (ja) 1996-08-06 1998-04-21 Otsuka Pharmaceut Factory Inc アデノシン増強剤
JPH10101671A (ja) 1996-08-08 1998-04-21 Otsuka Pharmaceut Factory Inc 一酸化窒素合成酵素阻害剤
AUPO395396A0 (en) 1996-12-02 1997-01-02 Fujisawa Pharmaceutical Co., Ltd. Benzamide derivatives
FR2757852B1 (fr) * 1996-12-31 1999-02-19 Cird Galderma Composes stilbeniques a groupement adamantyl, compositions les contenant et utilisations
JPH10212271A (ja) 1997-01-31 1998-08-11 Zeria Pharmaceut Co Ltd Ｎ−置換ベンゾイルアミン誘導体、それを含有する医薬及び該化合物の製造中間体
CA2319680C (en) 1997-02-07 2010-04-20 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
JPH10338658A (ja) 1997-04-08 1998-12-22 Hoechst Marion Roussel Kk レチノイド作用調節剤
JPH1129480A (ja) 1997-05-12 1999-02-02 Otsuka Pharmaceut Factory Inc 縮環ピリミジン誘導体を含有する医薬組成物
EP0995742A4 (en) * 1997-06-27 2004-08-25 Fujisawa Pharmaceutical Co SULPHONAMIDE COMPOUNDS AND THEIR MEDICAL USE
WO1999000359A1 (fr) 1997-06-27 1999-01-07 Fujisawa Pharmaceutical Co., Ltd. Derives de noyau aromatique
US6613942B1 (en) * 1997-07-01 2003-09-02 Novo Nordisk A/S Glucagon antagonists/inverse agonists
US6114483A (en) 1997-08-27 2000-09-05 E. I. Du Pont De Nemours And Company Polymerization of olefins
JPH11171848A (ja) 1997-09-26 1999-06-29 Fujirebio Inc 芳香族アミド誘導体
US6297239B1 (en) 1997-10-08 2001-10-02 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
AU9453098A (en) 1997-10-22 1999-05-10 Zeneca Limited Imidazole derivatives and their use as farnesyl protein transferase inhibit ors
WO1999024415A1 (fr) 1997-11-12 1999-05-20 Institute Of Medicinal Molecular Design, Inc. Agonistes du recepteur du retinoide
DK1042320T3 (da) 1997-11-21 2002-05-13 Astrazeneca Uk Ltd Nye forbindelser, som er P2-purinoceptor-7-transmembran (TM) G-proteinkoblede receptorantagonister
GB9725298D0 (en) 1997-11-28 1998-01-28 Zeneca Ltd Insecticidal thiazole derivatives
WO1999032477A1 (en) 1997-12-19 1999-07-01 Schering Aktiengesellschaft Ortho-anthranilamide derivatives as anti-coagulants
WO1999038845A1 (en) 1998-01-29 1999-08-05 Tularik Inc. Ppar-gamma modulators
JP3937367B2 (ja) 1998-02-05 2007-06-27 株式会社大塚製薬工場 一酸化窒素合成酵素阻害剤
JPH11292879A (ja) 1998-04-08 1999-10-26 Otsuka Pharmaceut Factory Inc カルボキサミド誘導体
DE19816780A1 (de) 1998-04-16 1999-10-21 Bayer Ag Substituierte 2-Oxo-alkansäure-[2-(indol-3-yl)-ethyl]amide
GB9811969D0 (en) * 1998-06-03 1998-07-29 Celltech Therapeutics Ltd Chemical compounds
DE19830431A1 (de) 1998-07-08 2000-01-13 Hoechst Marion Roussel De Gmbh Sulfonylamino-carbonsäure-N-arylamide als Guanylatcyclase-Aktivatoren
US6197798B1 (en) 1998-07-21 2001-03-06 Novartis Ag Amino-benzocycloalkane derivatives
JP4191825B2 (ja) 1998-09-10 2008-12-03 あすか製薬株式会社 ５−アミノイソキサゾール誘導体
GB9823871D0 (en) 1998-10-30 1998-12-23 Pharmacia & Upjohn Spa 2-Amino-thiazole derivatives, process for their preparation, and their use as antitumour agents
US6635657B1 (en) * 1998-12-23 2003-10-21 Eli Lilly And Company Aromatic amides
AU2871900A (en) 1999-02-04 2000-08-25 Millennium Pharmaceuticals, Inc. G-protein coupled heptahelical receptor binding compounds and methods of use thereof
RU2242469C2 (ru) * 1999-03-29 2004-12-20 Ф.Хоффманн-Ля Рош Аг Активаторы глюкокиназы
US6610846B1 (en) * 1999-03-29 2003-08-26 Hoffman-La Roche Inc. Heteroaromatic glucokinase activators
US6320050B1 (en) * 1999-03-29 2001-11-20 Hoffmann-La Roche Inc. Heteroaromatic glucokinase activators
DK1169312T3 (da) * 1999-03-29 2005-01-31 Hoffmann La Roche Glucokinaseaktivatorer
SG148834A1 (en) 1999-06-30 2009-01-29 Japan Tobacco Inc Compounds for the modulation of ppary activity
PL366110A1 (en) 1999-08-13 2005-01-24 Vertex Pharmaceuticals Incorporated Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases
NZ517426A (en) 1999-08-27 2004-04-30 Sugen Inc Phosphate mimics and methods of treatment using phosphatase inhibitors
GB9921684D0 (en) 1999-09-15 1999-11-17 Zeneca Ltd Assays
CA2385592C (en) * 1999-09-17 2011-01-11 Bing-Yan Zhu Benzamides and related inhibitors of factor xa
ES2270874T3 (es) 1999-10-08 2007-04-16 Affinium Pharmaceuticals, Inc. Inhibidores de fab i.
CA2389439A1 (en) 1999-11-04 2001-05-10 Ortho-Mcneil Pharmaceutical, Inc. Nonpeptide substituted benzothiazepines as vasopressin antagonists
WO2001035950A2 (en) * 1999-11-18 2001-05-25 Centaur Pharmaceuticals, Inc. Benzamide therapeutics and methods for treating inflammatory bowel disease
US6353111B1 (en) * 1999-12-15 2002-03-05 Hoffmann-La Roche Inc. Trans olefinic glucokinase activators
DE60115394T2 (de) 2000-02-29 2006-10-19 Millennium Pharmaceuticals, Inc., Cambridge Benzamide und ähnliche inhibitoren vom faktor xa
EP1132381A1 (en) 2000-03-08 2001-09-12 Cermol S.A. Ester derivatives of dimethylpropionic acid and pharmaceutical compositions containing them
AU776053B2 (en) 2000-03-31 2004-08-26 Astellas Pharma Inc. Diazepan derivatives or salts thereof
US6534651B2 (en) * 2000-04-06 2003-03-18 Inotek Pharmaceuticals Corp. 7-Substituted isoindolinone inhibitors of inflammation and reperfusion injury and methods of use thereof
EP1280801B1 (en) 2000-05-03 2005-09-07 F. Hoffmann-La Roche Ag Hydantoin-containing glucokinase activators
MXPA02010745A (es) * 2000-05-03 2003-03-10 Hoffmann La Roche Activadores de glucocinasa heteroaromaticos de alquinil-fenilo.
DK1282611T3 (da) 2000-05-08 2005-02-14 Hoffmann La Roche Substituerede phenylacetatamider og anvendelse deraf som glucokinaseaktivatorer
AU2001265914B2 (en) 2000-05-08 2005-11-03 F. Hoffmann-La Roche Ag Para-amine substituted phenylamide glucokinase activators
AU2001271637B2 (en) 2000-06-28 2006-05-04 Amgen, Inc. Quinolinyl and benzothiazolyl ppar-gamma modulators
MXPA03000365A (es) 2000-07-20 2003-05-27 Hoffmann La Roche Bencenacetamida substituida con alfa-acilo y alfa-heteroatomo como activadores de la glucocinasa.
US6369232B1 (en) 2000-08-15 2002-04-09 Hoffmann-La Roche Inc. Tetrazolyl-phenyl acetamide glucokinase activators
EP1322635B1 (en) 2000-09-25 2006-03-22 Janssen Pharmaceutica N.V. Farnesyl transferase inhibiting quinoline and quinazoline derivatives as farnesyl transferase inhibitors
WO2002026718A2 (en) 2000-09-29 2002-04-04 Millennium Pharmaceutical, Inc. Bicyclic pyrimidin-4-one based inhibitors of factor xa
US20040077690A1 (en) 2000-09-29 2004-04-22 Bing-Yan Zhu Quaternary amidino based inhibitors of factor xa
PL362546A1 (en) 2000-10-05 2004-11-02 Fujisawa Pharmaceutical Co, Ltd. Benzamide compounds as apo b secretion inhibitors
CN1283626C (zh) * 2000-11-22 2006-11-08 安斯泰来制药有限公司 取代苯衍生物或其盐
KR100545431B1 (ko) * 2000-12-06 2006-01-24 에프. 호프만-라 로슈 아게 축합된 이종방향족 글루코키나제 활성화제
US6482951B2 (en) 2000-12-13 2002-11-19 Hoffmann-La Roche Inc. Isoindolin-1-one glucokinase activators
WO2002051397A1 (fr) * 2000-12-22 2002-07-04 Ishihara Sangyo Kaisha, Ltd. Derives d'aniline ou sels de ceux-ci, ainsi qu'inhibiteurs de production de cytokine contenant ces derives
EP1217000A1 (en) 2000-12-23 2002-06-26 Aventis Pharma Deutschland GmbH Inhibitors of factor Xa and factor VIIa
WO2002062775A1 (fr) * 2001-02-02 2002-08-15 Yamanouchi Pharmaceutical Co., Ltd. Dérivé de 2-acylaminothiazole ou son sel
TWI243164B (en) 2001-02-13 2005-11-11 Aventis Pharma Gmbh Acylated indanyl amines and their use as pharmaceuticals
DE60221505D1 (de) 2001-03-30 2007-09-13 Millennium Pharm Inc FAKTOR Xa BENZAMIDIN INHIBITOREN
SE0102299D0 (sv) * 2001-06-26 2001-06-26 Astrazeneca Ab Compounds
SE0102300D0 (sv) * 2001-06-26 2001-06-26 Astrazeneca Ab Compounds
EP1431267A4 (en) * 2001-08-09 2004-12-22 Ono Pharmaceutical Co COMPOUNDS DERIVED FROM CARBOXYLIC ACID AND MEDICAMENTS COMPRISING SUCH COMPOUNDS AS ACTIVE INGREDIENT
TWI312274B (en) 2001-08-13 2009-07-21 Du Pont Method for controlling particular insect pests by applying anthranilamide compounds
SE0102764D0 (sv) 2001-08-17 2001-08-17 Astrazeneca Ab Compounds
EP1425286B1 (en) 2001-09-12 2007-02-28 Pharmacia & Upjohn Company LLC Substituted 7-aza-[2.2.1]bicycloheptanes for the treatment of diseases
TWI283164B (en) 2001-09-21 2007-07-01 Du Pont Anthranilamide arthropodicide treatment
DK1427415T3 (da) 2001-09-21 2009-11-23 Brystol Myers Squibb Company Forbindelser indeholdende lactam og derivater heraf som faktor Xa-hæmmere
AU2002334733B2 (en) 2001-10-01 2006-11-23 Arena Pharmaceuticals, Inc. MCH receptors antagonists
EP1336607A1 (en) 2002-02-19 2003-08-20 Novo Nordisk A/S Amide derivatives as glucokinase activators
WO2003047626A1 (en) 2001-12-03 2003-06-12 Novo Nordisk A/S Use of a glucokinase activator in combination with a glucagon antagonist for treating type 2 diabetes
US7176314B2 (en) 2001-12-05 2007-02-13 Amgen, Inc. Inflammation modulators
US20030187026A1 (en) 2001-12-13 2003-10-02 Qun Li Kinase inhibitors
US6911545B2 (en) 2001-12-19 2005-06-28 Hoffman-La Roche Inc. Crystals of glucokinase and methods of growing them
EP1458382A1 (en) 2001-12-21 2004-09-22 Novo Nordisk A/S Amide derivatives as gk activators
GB0202873D0 (en) 2002-02-07 2002-03-27 Novartis Ag Organic compounds
EP1496052B1 (en) 2002-03-26 2009-08-05 Banyu Pharmaceutical Co., Ltd. Novel aminobenzamide derivative
CN100357283C (zh) 2002-04-02 2007-12-26 中国科学院上海药物研究所 一类甲硫氨酰氨肽酶抑制剂
DE60309856T2 (de) 2002-04-26 2007-06-14 F. Hoffmann-La Roche Ag Substituierte phenylacetamide und deren verwendung als glucokinaseaktivatoren
US20070231874A1 (en) 2002-05-16 2007-10-04 Kenji Kamata Crystal of glucokinase protein, and method for drug design using the crystal
WO2004002481A1 (en) 2002-06-27 2004-01-08 Novo Nordisk A/S Aryl carbonyl derivatives as therapeutic agents
AU2003252478A1 (en) * 2002-07-10 2004-02-02 Ono Pharmaceutical Co., Ltd. Ccr4 antagonist and medicinal use thereof
AU2003263393A1 (en) 2002-09-04 2004-03-29 Glenmark Pharmaceuticals Limited New heterocyclic amide compounds useful for the treatment of inflammatory and allergic disorders: process for their preparation and pharmaceutical compositions containing them
PL375149A1 (en) 2002-10-03 2005-11-28 F.Hoffmann-La Roche Ag Indole-3-carboxamides as glucokinase (gk) activators
EP1549626A1 (en) 2002-10-03 2005-07-06 Novartis AG Substituted (thiazol-2-yl) -amide or sulfonamide as glycokinase activators useful in the treatment of type 2 diabetes
GB0226931D0 (en) * 2002-11-19 2002-12-24 Astrazeneca Ab Chemical compounds
GB0226930D0 (en) 2002-11-19 2002-12-24 Astrazeneca Ab Chemical compounds
MY141521A (en) 2002-12-12 2010-05-14 Hoffmann La Roche 5-substituted-six-membered heteroaromatic glucokinase activators
PT1585739E (pt) 2003-01-06 2011-05-13 Lilly Co Eli Arilciclopropilacetamidas substitu?das como activadores da glucocinase
AU2003294376A1 (en) 2003-01-06 2004-08-10 Eli Lilly And Company Heteroaryl compounds
EP1594863A1 (en) 2003-02-11 2005-11-16 Prosidion Limited Tri(cyclo) substituted amide glucokinase activator compounds
PL378117A1 (pl) 2003-02-11 2006-03-06 Prosidion Limited Tricyklopodstawione związki amidowe
BRPI0407283A (pt) 2003-02-13 2006-01-31 Banyu Pharma Co Ltd Composto, composição farmacêutica, e, agente ativador de glucoquinase, agentes terapêuticos e/ou agentes preventivos para diabetes melito e obesidade
NZ541824A (en) * 2003-02-26 2010-04-30 Banyu Pharma Co Ltd Heteroarylcarbamoylbenzene derivatives as glucokinase activators
TW200505902A (en) 2003-03-20 2005-02-16 Schering Corp Cannabinoid receptor ligands
MXPA05010081A (es) 2003-03-24 2005-11-23 Hoffmann La Roche Bencil-piridazinonas como inhibidores de transcriptasa inversa.
EP1628666B1 (en) 2003-05-14 2015-09-23 NeuroGenetic Pharmaceuticals, Inc. Compouds and uses thereof in modulating amyloid beta
EP1635832A2 (en) 2003-06-06 2006-03-22 Merck & Co., Inc. Combination therapy for the treatment of diabetes
GB0325402D0 (en) 2003-10-31 2003-12-03 Astrazeneca Ab Compounds
CA2545711A1 (en) 2003-11-13 2005-06-02 Ambit Biosciences Corporation Urea derivatives as kinase modulators
EP1532980A1 (en) 2003-11-24 2005-05-25 Novo Nordisk A/S N-heteroaryl indole carboxamides and analogues thereof, for use as glucokinase activators in the treatment of diabetes
GB0327760D0 (en) 2003-11-29 2003-12-31 Astrazeneca Ab Compounds
GB0327761D0 (en) 2003-11-29 2003-12-31 Astrazeneca Ab Compounds
GB0328178D0 (en) 2003-12-05 2004-01-07 Astrazeneca Ab Compounds
NZ548128A (en) 2003-12-29 2010-05-28 Banyu Pharma Co Ltd Novel 2-heteroaryl-substituted benzimidazole derivative
AU2005203930C1 (en) 2004-01-06 2012-02-23 Vtv Therapeutics Llc Heteroaryl-ureas and their use as glucokinase activators
EP1718625A1 (en) 2004-02-18 2006-11-08 AstraZeneca AB Compounds
KR20070007103A (ko) 2004-02-18 2007-01-12 아스트라제네카 아베 벤즈아미드 유도체 및 이의 글루코키나아제 활성화제로서의용도
JPWO2005090332A1 (ja) 2004-03-23 2008-01-31 萬有製薬株式会社 置換キナゾリン又はピリドピリミジン誘導体
AU2005229416B2 (en) 2004-04-02 2009-03-26 Novartis Ag Sulfonamide-thiazolpyridine derivatives as glucokinase activators useful the treatment of type 2 diabetes
RU2006138426A (ru) 2004-04-02 2008-05-10 Новартис АГ (CH) Производные тиазолопиридина, содержащие их фармацевтические композиции и способы лечения состояний, опосредованных глюкокиназой
JP2007533722A (ja) 2004-04-21 2007-11-22 プロシディオン・リミテッド トリ（シクロ）置換アミド化合物
TW200600086A (en) 2004-06-05 2006-01-01 Astrazeneca Ab Chemical compound
US20080026987A1 (en) 2004-06-17 2008-01-31 Novo Nordisk A/S Use of Liver-Selective Glucokinase Activators
JP2008509898A (ja) 2004-08-12 2008-04-03 プロシディオン・リミテッド 置換されたフェニルアセトアミドおよびグルコキナーゼ活性化剤としてのこれらの使用
GB0418046D0 (en) 2004-08-12 2004-09-15 Prosidion Ltd Eantioselective process
GB0418058D0 (en) 2004-08-12 2004-09-15 Prosidion Ltd Fluorination process
GB0423043D0 (en) 2004-10-16 2004-11-17 Astrazeneca Ab Compounds
GB0423044D0 (en) 2004-10-16 2004-11-17 Astrazeneca Ab Compounds
WO2006040527A1 (en) 2004-10-16 2006-04-20 Astrazeneca Ab Process for making phenoxy benzamide compounds
DE602004018552D1 (de) 2004-12-24 2009-01-29 Telecom Italia Spa Verfahren zur optimierung des webseitenzugangs in drahtlosen netzwerken
US8859581B2 (en) 2005-04-25 2014-10-14 Merck Patent Gmbh Azaheterocyclic compounds as kinase inhibitors
EP1891069A1 (en) 2005-05-24 2008-02-27 AstraZeneca AB 2-phenyl substituted imidazol [4,5b]pyridine/ pyrazine and purine derivatives as glucokinase modulators
TW200714597A (en) 2005-05-27 2007-04-16 Astrazeneca Ab Chemical compounds
JP2009500442A (ja) 2005-07-09 2009-01-08 アストラゼネカ アクチボラグ ２型糖尿病を処置するためのグルコキナーゼのモジュレーターとしての２−ヘテロシクリルオキシベンゾイルアミノヘテロシクリル化合物
US7642259B2 (en) 2005-07-09 2010-01-05 Astrazeneca Ab Heteroaryl benzamide derivatives for use as GLK activators in the treatment of diabetes
US20080234273A1 (en) 2005-07-09 2008-09-25 Mckerrecher Darren Heteroaryl Benzamide Derivatives for Use as Glk Activators in the Treatment of Diabetes
EP1915367A1 (en) 2005-08-09 2008-04-30 AstraZeneca AB Heteroarylcarbamoylbenzene derivatives for the treatment of diabetes
JP2007063225A (ja) 2005-09-01 2007-03-15 Takeda Chem Ind Ltd イミダゾピリジン化合物
EP1928874A1 (en) 2005-09-16 2008-06-11 AstraZeneca AB Heterobicyclic compounds as glucokinase activators
EP1951707A1 (en) 2005-11-01 2008-08-06 Janssen Pharmaceutica N.V. Substituted pyrrolones as allosteric modulators of glucokinase
TW200738621A (en) 2005-11-28 2007-10-16 Astrazeneca Ab Chemical process
TW200825063A (en) 2006-10-23 2008-06-16 Astrazeneca Ab Chemical compounds
SA07280576B1 (ar) 2006-10-26 2011-06-22 استرازينيكا ايه بي مركبات بنزويل أمينو سيكليل غير متجانسة بأعتبارها عوامل منشطة للجلوكوكيناز
BRPI0721143A2 (pt) 2006-12-21 2014-03-11 Astrazeneca Ab Forma cristalina do composto processo para a formação da mesma, uso de um composto, método para tratar doenças mediadas por ativador de glicocinase

Also Published As

Publication number Publication date
DE60227119D1 (de) 2008-07-24
DK1568367T3 (da) 2007-07-30
HK1089960A1 (en) 2006-12-15
EP1661563A1 (en) 2006-05-31
US7390908B2 (en) 2008-06-24
ATE359781T1 (de) 2007-05-15
DE60219698T2 (de) 2007-12-27
EP1568367B3 (en) 2009-09-02
DE60226914D1 (de) 2008-07-10
PL368970A1 (en) 2005-04-04
DE60210782T2 (de) 2007-05-10
KR100920439B1 (ko) 2009-10-08
DE60227121D1 (de) 2008-07-24
ATE397926T1 (de) 2008-07-15
DE60227122D1 (de) 2008-07-24
RU2329043C9 (ru) 2008-11-20
ATE396720T1 (de) 2008-06-15
JP3987829B2 (ja) 2007-10-10
DK1529530T3 (da) 2006-11-13
EP1661568A1 (en) 2006-05-31
EP1529530B1 (en) 2006-08-02
TWI333855B (en) 2010-12-01
ES2307239T3 (es) 2008-11-16
CY1107683T1 (el) 2013-04-18
CY1108254T1 (el) 2014-02-12
ES2270263T7 (es) 2010-03-31
ES2309862T3 (es) 2008-12-16
DK1529530T5 (da) 2009-11-23
SE0102764D0 (sv) 2001-08-17
DK1661569T3 (da) 2008-09-15
EP1568367A1 (en) 2005-08-31
DE60213678D1 (de) 2006-09-14
ES2306300T3 (es) 2008-11-01
SI1529530T1 (sl) 2006-12-31
EP1669068B1 (en) 2008-06-11
ATE397928T1 (de) 2008-07-15
ATE334678T1 (de) 2006-08-15
PT1661569E (pt) 2008-08-18
EP1529530A1 (en) 2005-05-11
SI1661563T1 (sl) 2008-10-31
PT1661563E (pt) 2008-07-31
ATE406891T1 (de) 2008-09-15
AR037898A1 (es) 2004-12-22
EP1674097B1 (en) 2008-06-11
HK1089966A1 (en) 2006-12-15
DE60228770D1 (de) 2008-10-16
TW200911238A (en) 2009-03-16
KR20040030125A (ko) 2004-04-08
ES2312050T3 (es) 2009-02-16
NO20040686L (no) 2004-02-17
ES2270263T3 (es) 2007-04-01
CN101584691A (zh) 2009-11-25
EP1669069B1 (en) 2008-09-10
HK1090291A1 (en) 2006-12-22
HK1093429A1 (en) 2007-03-02
JP2005320343A (ja) 2005-11-17
CA2457410A1 (en) 2003-02-27
EP1987831A1 (en) 2008-11-05
HK1089958A1 (en) 2006-12-15
PT1529530E (pt) 2006-11-30
WO2003015774A1 (en) 2003-02-27
ES2307238T3 (es) 2008-11-16
EP1669069A1 (en) 2006-06-14
US7951830B2 (en) 2011-05-31
HK1079692A1 (en) 2006-04-13
PT1568367E (pt) 2007-06-28
EP1568367B1 (en) 2007-04-18
ZA200401015B (en) 2005-05-06
MY146279A (en) 2012-07-31
ATE397927T1 (de) 2008-07-15
DE60228143D1 (de) 2008-09-18
HK1090839A1 (en) 2007-01-05
DK1661563T3 (da) 2008-08-25
SI1669068T1 (sl) 2008-10-31
EP1661569B1 (en) 2008-06-11
RU2329043C2 (ru) 2008-07-20
ATE323487T1 (de) 2006-05-15
CN101492416A (zh) 2009-07-29
CN101492416B (zh) 2012-02-22
EP1529530B3 (en) 2009-09-02
CY1108267T1 (el) 2014-02-12
CO5560563A2 (es) 2005-09-30
IL203923A (en) 2013-03-24
HUP0401213A3 (en) 2011-03-28
CA2457410C (en) 2011-09-27
EP1661567A1 (en) 2006-05-31
DE60219698T3 (de) 2010-02-25
ES2312051T3 (es) 2009-02-16
ES2307237T3 (es) 2008-11-16
IL160219A0 (en) 2004-07-25
CN100577163C (zh) 2010-01-06
DE60219698D1 (de) 2007-05-31
EP1661563B1 (en) 2008-05-28
ATE407672T1 (de) 2008-09-15
EP1695705B1 (en) 2008-08-06
HK1090292A1 (en) 2006-12-22
NZ531193A (en) 2005-07-29
ATE403427T1 (de) 2008-08-15
AU2002321462B2 (en) 2007-09-20
ATE397929T1 (de) 2008-07-15
EP1661567B1 (en) 2008-06-11
ES2308609T3 (es) 2008-12-01
DE60227120D1 (de) 2008-07-24
ES2285341T7 (es) 2010-03-31
HUP0401213A2 (hu) 2004-12-28
DE60210782D1 (de) 2006-05-24
CN101704797A (zh) 2010-05-12
US20050080106A1 (en) 2005-04-14
CY1105746T1 (el) 2010-12-22
RU2004104333A (ru) 2005-03-27
EP1661569A1 (en) 2006-05-31
UA83182C2 (en) 2008-06-25
JP2005525291A (ja) 2005-08-25
US20090227592A1 (en) 2009-09-10
PT1669068E (pt) 2008-08-20
BR0212008A (pt) 2004-09-28
HK1076042A1 (en) 2006-01-06
EP1669068A1 (en) 2006-06-14
EP1420784A1 (en) 2004-05-26
EP1661568B1 (en) 2008-09-03
IS7150A (is) 2004-02-13
DE60213678T2 (de) 2007-08-09
DK1669068T3 (da) 2008-09-22
ES2285341T3 (es) 2007-11-16
EP1420784B1 (en) 2006-04-19
CY1108276T1 (el) 2014-02-12
SI1568367T1 (sl) 2007-08-31
SI1661569T1 (sl) 2008-10-31
US7524957B2 (en) 2009-04-28
DE60228897D1 (de) 2008-10-23
JP4441446B2 (ja) 2010-03-31
HK1064598A1 (en) 2005-02-04
DK1568367T5 (da) 2009-11-23
US20080207636A1 (en) 2008-08-28
EP1695705A1 (en) 2006-08-30
CN1568185A (zh) 2005-01-19
DE60213678T3 (de) 2010-02-25
EP1674097A1 (en) 2006-06-28

Similar Documents

Publication Publication Date Title
MXPA04001500A (es) Compuestos que tienen un efecto sobre la glucocinasa.
HK1062888A1 (en) Vinyl phenyl derivatives as glk activators
SE0102300D0 (sv) Compounds
MY136034A (en) New medicaments for the treatment of chronic obstructive pulmonary disease
IL171977A (en) Cyclic sulfonamide for inhibition of gamma-secretase, process for its preparation and a pharmaceutical composition comprising the same
AU2003282234A1 (en) Benzofuran derivates, process for their preparation and intermediates thereof
JO2353B1 (en) New derivatives of mixed-ring fluoroglycosides and drugs containing these compounds and their use
HK1094425A1 (en) Substituted 2-aminotetralines for the preventive treatment of parkinson's disease
EP1609798A4 (en) CONDENSED HETEROCYCLIC DERIVATIVE, MEDICAL COMPOSITION, AND MEDICAL USE THEREOF
CA2368347A1 (en) Glucokinase activators
WO2006005609A3 (de) Substituierte oxindol-derivate und diese enthaltende arzneimittel
MXPA04005156A (es) Antagonistas del receptor de adenosina a2a.
GB0112348D0 (en) Compounds
WO2005037798A3 (en) Amide or thiomide derivatives and their use in the treatment of pain
MY135218A (en) 2,6-quinolinyl and 2,6-naphthyl derivatives and their use in the treatment of vla-4 dependent diseases
GB0109122D0 (en) Novel compounds
ATE372995T1 (de) Benzo(b)(1,4)dioxepinderivate
IL166057A0 (en) Urea-substituted and urethane-substituted acylureas methods for the production thereof and their useas medicaments
MXPA04001419A (es) Isoxazolopiridinonas y su uso en el tratamiento de enfermedad de parkinson.
MY139613A (en) Novel piperazinyl-pyrazinone derivatives for the treatment of 5-ht2a receptor-related disorders
WO2004048381A3 (en) Pyrazoloazepine compounds as pharmaceutical agents
TW200505892A (en) Substituted 3-(benzoylureido)thiophene derivatives, processes for preparing them and their use
AU2003213896A1 (en) Process to obtain dibenzylbutyrolactonic lignans; process to obtain synthetic derivatives from lignanes bearing anti-chagas chemoprophylactic and therapeutical activities
TW200509915A (en) Novel oxazoles, their manufacture and use as pharmaceutical agents
MXPA05010135A (es) Nuevos derivados de oxazol, procedimiento para su fabricacion y uso como agentes farmaceuticos.

Legal Events

Date Code Title Description
FG Grant or registration